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Efficient intracellular delivery is essential for high activity of nucleic acids based therapeutics, including antisense agents.
Several strategies have been developed and practically all rely on auxiliary transfection reagents such as cationic lipids,
cationic polymers and cell penetrating peptides as complexing agents and carriers of the nucleic acids. However, uptake
mechanisms remain rather poorly understood, and protocols always require optimization of transfection parameters.
Considering that cationic transfection complexes bind to and thus may up-concentrate on the cell surface, we have now
quantitatively compared the cellular activity (in the pLuc705 HeLa cell splice correction system) of PNA antisense
oligomers using lipoplex delivery of cholesterol- and bisphosphonate-PNA conjugates, polyplex delivery via a PNA-
polyethyleneimine conjugate and CPP delivery via a PNA-octaarginine conjugate upon varying the cell culture
transfection volume (and cell density) at fixed PNA concentration. The results show that for all delivery modalities the
cellular antisense activity increases (less than proportionally) with increasing volume (in some cases accompanied with
increased toxicity), and that this effect is more pronounced at higher cell densities. These results emphasize that
transfection efficacy using cationic carriers is critically dependent on parameters such as transfection volume and cell
density, and that these must be taken into account when comparing different delivery regimes.
Introduction
Efficient intracellular delivery is essential for high activity of
nucleic acid based therapeutics including antisense agents. In
contrast to most small molecule drugs which are taken up by cells
via (passive) diffusion through the lipid cell membrane, oligo-
nucleotides and other antisense oligomers, such as peptide nucleic
acids (PNAs) and phosphorodiaminidate morpholino oligomers
(PMOs), require a carrier for cellular uptake due to their large size
and hydrophilic character (in the case of oligonucleotides even
high negative charge). Effective delivery vehicles are typically poly-
cationic, in the form of cationic lipids, polyamines or (cationic)
cell penetrating peptides. These vehicles form complexes with the
negatively charged oligonucleotides, but the resulting lipoplexes
and polyplexes also require an overall positive zeta potential for
efficacy. The positive charge enables the carrier to interact with
the cell membrane and internalize into the cytosol, generally via
endocytotic pathways.
1
Following cellular uptake, lipoplexes destabilize the endosomal
membrane, resulting in a flip-flop reorganization of phospho-
lipids. These phospholipids then diffuse into the lipoplex and
interact with the cationic lipids, causing the DNA to dissociate
and diffuse into the cytosol.
1 Lipoplexes have successfully been
employed for cellular delivery of DNA and nucleic acid analogs
by complexation via electrostatic interaction. However, charge
neutral antisense oligomers like peptide nucleic acids (aegPNAs)
or PMOs do not interact with the cationic lipid themselves, and
several modifications have been developed in order to increase the
affinity of the PNA for the cationic liposome carrier. Lipophilic
or negatively charged moieties have been conjugated to PNA to
facilitate hydrophobic or ionic interactions, respectively, with the
cationic lipids, and PNA/DNA heteroduplexes have been
prepared with partially overlapping single-stranded carrier DNA
which then promotes complexation.
2 Examples of hydrophobic/
anionic PNA conjugates which have shown potent transfection
efficiency are the introduction of negative charges through
coupling with bis-phosphonate
3 and lipid conjugation to fatty
acids, heteroaromatic compounds, cholic acid or cholesterol
moieties.
4-6
An alternative to cationic lipids is the use of cationic polymers
that can be complexed (or chemically conjugated) to the nucleic
acid, forming cationic polyplexes (or nanoparticles). The most
extensively used cationic polymer for transfection is poly(ethyl-
enimine) (PEI).
7 The high amine content and buffering capacity
of PEI is hypothesized to be the main driving force of its
efficiency, resulting in an endosomal import of protons, high
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osmotic pressure and subsequent rupture of the endosomes
without need of additional endosomolytic activity. PEI is com-
mercially available in a large molecular weight range and various
degrees of branching making it highly versatile in preparations.
Furthermore, it is readily modified by various chemical strategies
to alter its physicochemical character or to confer transfection
specificity by attaching ligands for cell targeting.
1 Also, PEI has
been shown to increase transfection efficacy when conjugated to a
PNA oligomer via an intracellularly cleavable linker.
8
Cell penetrating peptides (CPPs), a group of cationic peptides
typically containing multiple arginines, are effectively taken up
by eukaryotic cells and can be used to deliver conjugated mole-
cular cargos into the cell.
9 The initial reports suggested that
positively charged CPPs interact with negatively charged com-
ponents of the membrane, like heparin sulfate, as well as the
phospholipid bilayer, and were internalized by membrane destabi-
lization or pore formation. A large number of recent studies have,
however, demonstrated that cellular uptake of CPPs mainly takes
place by endocytotic pathways.
10 Conjugation to such peptides is
also a useful technique for the delivery of peptide nucleic acids,
presenting several advantages like availability through continuous
solid phase-synthesis and avoidance of lipid transfection reagents.
However, endosomal escape is generally limited and requires the
use of endosomal disrupting agents like chloroquine, calcium
ions, lipophilic photosensitizers or sucrose.
10-12 Furthermore,
chemical modifications of CPPs, such as conjugation to a lipid
domain (CatLip conjugate), have been found to significantly
improve their delivery efficacy.
13-15
Cationic lipoplexes and polyplexes associate with the cell sur-
face, and such up-concentration may result in enhanced cellular
uptake.
15,16 This phenomenon has also been observed for cell
penetrating peptides, for which cellular uptake exhibited volume-
dependent behavior.
17 In order to directly compare this effect
on different delivery modalities we have taken advantage of the
antisense system based on PNA targeting to the cryptic splice
site within the mutated luciferase gene in HeLa pLuc705 cells.
18
This system permits the use of different delivery vehicles with
PNA oligomers optimized to the delivery agent but of identical
sequence. Thus we have employed lipoplex delivery of cholesterol-
PNA and bisphosphonate-PNA conjugates, polyplex delivery via
a PNA-PEI conjugate and CPP delivery via a PNA-octaarginine
conjugate, and quantitatively compared the antisense effects upon
varying the cell culture transfection volume (and cell density) at
fixed PNA concentration.
The results show that for all delivery modalities the cellular
antisense activity increases (less than proportionally) with increas-
ing volume and that this effect is more pronounced at higher cell
densities. These results emphasize that transfection efficacy using
cationic carriers is critically dependent on parameters such as
transfection volume and cell density, and that these must be taken
into account when comparing different delivery regimes.
Results
A large number of methods are available for nucleic acid cellular
transfection and typically require careful optimization for use.
However, despite the fact that cationic transfection reagents cause
up-concentration of the (nucleic acid) cargo on the cell mem-
brane, the effect of the volume of the transfection medium is
rarely considered in experimental protocols. Thus in a compar-
ative study across different cationic delivery modalities we set
out to study this effect using different volumes of PNA-lipoplex,
-polyplex or PNA-CPP preparations exploiting different PNA
modifications (Table 1) designed for use with these delivery
modalities.
In order to define initial conditions, PNA doses, transfection
reagents and incubation time were individually optimized for
each PNA modification according to transfection efficacy and
toxicity data. Conditions showing the highest antisense activity
above 50% cell viability were selected for further volume-effect
assays (data not shown). Subsequently, transfection solutions were
prepared specifically for each PNA conjugation. PNAs were either
complexed with a cationic lipid reagent (Lipofectamine 2000),
chemically conjugated to a cationic polymer (PEI), or for CPP-
PNAs, mixed with CQ as a singular preparation at their optimal
concentrations and transfected to HeLa pLuc705 cells for 24 h.
All tested PNA modifications contained a PNA oligomer of
identical sequence targeting the cryptic splice site within the
luciferase gene in HeLa pLuc705 cells and antisense activity (and
thus be inference cellular uptake) was measured as induced
luciferase activity.
18
In view of the previous evidence of the up-concentration of
cell-penetrating peptides on the cell surface,
17 our first choice
for studying the volume effect of transfection solutions was
the CPP-PNA conjugate. First we examined the effect of the
CPP-PNA modification on HeLa pLuc705 cells at 4 mM PNA
and 8  10
3 cells/well (in order to have 50% confluency at the
transfection time, which is the typical cell confluency for ordinary
Table1. List of PNAs
PNA No Name Sequence*
2977 Chol-hs-PNA Cholesteryl hemisuccinate-CCT CTT ACC TCA GTT ACA-NH2
3325 bP6-PNA H-[Lys-(Bis-phosphonate)]6-CCT CTT ACC TCA GTT ACA-NH2
2787 (D-Arg)8-PNA H-(D-Arg)8-Gly-CCT CTT ACC TCA GTT ACA-NH2
3140 PEI-PNA** PEI25K-(PEG8-SS-Ac-Cys-CCT CTT ACC TCA GTT ACA-NH2)15
*The sequences of the PNAs are written from N-terminal to C-terminal end. **Primary amines were reacted with SPDP-PEG8 reagent containing an
N-hydroxysuccinimide (NHS) ester and a sulfhydryl-reactive pyridyl disulfide group which could further be reacted with a cysteine-PNA. PEI25k was on
average modified with 15 SPDP-PEG8 per polymer.
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transfection). Under these conditions hardly any
volume effect was observed (Fig.1). This lack of
effect could be due to saturation of the cells
at this PNA concentration, and we therefore
decided to increase the cell number range in steps
from 4 to 32  10
3 cells/well in order to obtain
lower PNA-to-cell ratios. By using 24 or 32 
10
3 cells/well we observed around 2-fold efficacy
increase at six relative volumes (Fig.1), but cell
viability was also reduced comparably (Fig. S1).
These results do confirm that transfection effi-
cacy depends on PNA-to-cell ratio, in accordance
with previous conclusions,
16,17 and also indicate
that saturation may be possible at lower cell
numbers.
Next we analyzed an anionic PNA conjugate
which can form a complex with cationic lipids in
analogy to negatively charged nucleic acids.
3 A
bis-phosphonate-PNA conjugate was transfected
at different concentrations (0–2 nM) using vary-
ing volumes of the transfection solution/well
in a 96 well plate seeded at 24  10
3 cells/well.
Results showed that antisense activity increased
in a PNA dose-dependent manner at all trans-
fection volumes, and in parallel, increasing
volume also showed a higher antisense activity
up to four relative volumes where a saturation
was reached. We also observe from these experi-
ments that the volume-effect is more pronounced
at higher PNA concentrations. Whereas antisense
activity at 1 and 2 nM PNA doses showed an
approximately 2-fold increase at 4 relative
volumes, at 0.5 and 0.25 nM PNA doses it was
only about 1.75- and 1.5-fold, respectively
(Fig.2). However, the difference in PNA-
Lipofectamine ratio, resulting in decreasing zeta
potential as the PNA concentration increases at
fixed Lipofectamine concentration, may also
play a role, although an opposite effect could
be expected as lowering of the zeta potential
would decrease transfection efficacy. Cell viabi-
lity exhibited a slight decrease (, 30%) with
increasing transfection volume, but showed no
dependence on PNA concentration (Fig. S2).
As an example of a PNA polyplex for which
the zeta potential is only marginally affected by
the PNA we chose a cholesteryl-PNA conjugate
(PNA 2977, Table 1).
6 For this PNA modifica-
tion we also observed a clear volume-dependent
antisense activity at both 30 and 100 nM con-
centration (Fig.3). Furthermore, the activity increased nearly
linearly with the LFA2000 concentrations (2, 4 and 6 ml/ml),
whereas only minor effects were observed on cell viability even
for the highest PNA dose (Fig. S3). However, while at 30 nM
PNA concentration the transfection efficacy was increasing for
all relative volumes, this was limited to three relative volumes at
100 nM (Fig.3).
In order to test the generality of the effect, two of the PNAs,
CPP-PNA and cholesteryl-PNA, were transfected at the same
conditions in a 24-well plate (instead of 96-well plate) with
Figure1. Relative cellular luciferase antisense activity in HeLa pLuc 705 cells of PNA
conjugated to octa-arginine [(D-Arg)8-PNA]. Different cell numbers were plated in a 96-well
plate the day before transfection. Cells were treated with different volumes (50 ml/well for a
relative volume 1) of the transfection solution for 24 h: 4 mM PNA and 120 mM CQ. Cell
samples were then subjected to luciferase analysis and cellular viability test. All tests were
performed in duplicate and the results are given as average values ± standard deviations
(SD). Luciferase activity was analyzed using Bright-Glo reagent (Promega), normalized to cell
viability (Figs. S1–5) and given as relative light units (RLU/cell).
Figure2. Relative cellular luciferase antisense activity of phosphonate-conjugated PNA (bP6-
PNA). HeLa pLuc705 cells were trypsinized and seeded (2.4  10
4 cells/well) in a 96 well plate
the day before transfection. Cells were treated with different volumes (50 ml/well for a relative
volume 1) of the transfection solutions for 24 h: 0.25 to 2nM PNA complexed with 6 ml/ml
LFA2000. Cell samples were then subjected to luciferase analysis and cellular viability test.
All tests were performed in triplicate and the results are given as average values ± standard
deviations (SD). Luciferase activity was analyzed using Bright-Glo reagent (Promega),
normalized to cell viability (Figs. S1–5) and given as relative light units (RLU/cell).
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equivalent cell confluency. Both conjugates showed an increase
of the antisense activity with increasing transfection volume
(Fig. S5), fully consistent with the results obtained in the 96 well
plates.
Finally, we studied the volume-effect for a PNA-polyplex using
a disulfide coupled PNA-PEI (polyethyleneimine) conjugate.
8 A
4-fold antisense activity increase at 5 relative volumes was seen for
both of the analyzed doses (1 and 2 mM), but in contrast to the
other PNA conjugates, the transfection volume-effect for the
PEI-PNA is not dependent on the PNA dose (at 1 and 2 mM),
and showed a close to proportional dependence on the volume
up to 4 relative volumes (Fig.4), whereas only minor effect of
the cell number was observed. Finally, the PNA-polyplexes
exhibited a pronounced volume-dependent cellular toxicity at
the lower cell densities (4 and 8  10
3 cells/well) and the higher
concentration (2 mM) (Fig. S4).
Discussion
The present results unequivocally demonstrate that
antisense activity increases by increasing the volume
of the transfection solution for all four PNA com-
plexes and conjugates, supporting that cationic PNA-
lipolexes, PNA-PEI polyplexes as well as PNA-CPP
conjugates have high affinity for the cell surface and
that such cellular binding is important, or even
necessary, for cellular uptake. This is fully consistent
with previous reports, demonstrating that cell uptake
of DNA can be enhanced by an increase of nucleic
acid concentration on the target cell surface.
16
Although a slight volume-dependent decrease in cell
viability was observed under some conditions, the
results show that lower PNA doses could be used at
higher volumes to obtain higher transfection efficiency
without concomitant increase in cellular toxicity.
These results emphasize that transfection efficacy
using cationic carriers is critically dependent on para-
meters such as transfection volume and cell density,
and that these can be optimized and must be taken
into account when comparing different delivery regimes.
We believe that these conclusions are also valid to
any nucleic acid transfection (DNA, RNA and
analogs) that is performed by cationic transfection
reagents (cationic lipids, cationic polymers or CPP
conjugation).
Materials and Methods
Cell line and cultura media. HeLa pLuc705 cells
18
were purchased from Gene Tools (Philomath). Cells
were grown in RPMI1640 medium (Sigma) supple-
mented with 10% fetal bovine serum (FBS, Sigma),
1% glutamax (Gibco, Invitrogen), and 100 mg/ml
streptomycin (Gibco) at 37°C in a humidified
atmosphere with 5% CO2.
PNA synthesis. Nomenclatures and sequences of
the PNAs used in this study are listed in Table1. PNA
synthesis was performed by the standard Boc strategy as reported
previously.
19 The resulting PNA conjugates were purified by
HPLC and characterized by MALDI-TOF mass spectrometry.
The PNAs were lyophilized and stored at 4°C until use.
CPP-PNA. Peptides were linked to the PNA at the N-terminal
through glycine via continuous solid phase synthesis.
13
Bis-phosphonate-PNA. Lysine bis-phosphonate monomers were
covalently linked to PNA at the N-terminal on the solid support
via continuous synthesis using Fmoc-chemistry.
3
Cholesterol-hemisuccinate-PNA. Cholesterol-hemisuccinate was
covalently linked to the PNA N-terminal amino group via
solution conjugation.
6
PEI-PNA. PEI-PEGP15 was prepared from 25 kDa (Mw)
branched polyethylenimine (Sigma) and a heterobifunctional
linker (amine- and thiol-reactive) with a discrete 8-mer PEG
spacer, SPDP-PEG8 (Quanta Biodesign) as previously described.
8
Figure3. Relative cellular luciferase antisense activity of PNA conjugated to cholesteryl
hemisuccinate (Chol-hs-PNA). HeLa pLuc705 cells were trypsinized and seeded
(8  10
4 cells/well) in a 96 well plate the day before transfection. Cells were treated with
different volumes (50 ml/well for a relative volume 1) of the transfection solutions for
24 h: (A) 30 nM and (B) 100 nM PNA complexed with 2, 4 or 6 ml/ml LFA2000. Cell
samples were then subjected to luciferase analysis and cellular viability test. All tests
were performed in triplicate and the results are given as average values ± standard
deviations (SD). Luciferase activity was analyzed using Bright-Glo reagent (Promega),
normalized to cell viability (Figs. S1–5) and given as relative light units (RLU/cell).
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Briefly, 5 mg PEI (~0.2 mmol calc. from Mw or ~35 mmol
R-NH2) in 1.8 mL phosphate buffer, pH 7.4, was mixed with
5 mmol SPDP-PEG8 (theo. twenty-five PEG8-PDP per PEI) in
200 ml DMSO and incubated at RT for 8 h. The product
was dialyzed (Spectra/Por 2, MWCO: 12–14 kDa, Spectrum
Laboratories) and characterized by spectrophotometric quantifica-
tion of pyridine-2-thione released by DTT cleavage of the linker
and quantification of primary amines in PEI with a TNBS assay.
This was subsequently used to determine a modification degree of
averagely 15 PEG8-PDP per PEI (PEI-PEGP15). The PEG8-PDP
modified PEI was kept in freeze stock until it was conjugated to
Cys-PNA just before transfection (see ‘PNA transfection’).
PNA stock solutions at 200 mM in water were kept at 4°C
until use (Cys-PNA was stored at -20°C and kept at 4°C until
immediately before coupling to PEI).
PNA transfection. Exponentially growing cells
were cultured with antibiotic-free growth medium in
96- or 24-well plates the day before transfection at
different cell numbers.
Cholesterol and phosphonate PNAs. Lipofect-
AMINE2000 (LFA2000, Invitrogen) was used for
the transfection of the PNAs with Cholesterol
(PNA2977) and phosphonate (PNA3325) modifica-
tions. LFA2000 was diluted with OPTI-MEM
(Gibco) and mixed with an equal volume of the
PNA in H2O solution to the desired concentrations;
being J of the final transfection volume. This solu-
tion was incubated for 10 min at room temperature
and then mixed with RPMI1640 medium without
antibiotics (L of the final transfection volume) to the
desired final volume. Growth medium was removed
from cells and replaced by the transfection solution.
Cells were incubated for 24 h at 37°C and subjected
to further analysis.
Cell-penetratingpeptide-PNA. CPP-PNA (PNA2787)
was diluted in H2O at the desired concentrations, to
a J of the final transfection volume. Chloroquine
(CQ, Sigma) was diluted in OPTI-MEM to a L of
the final volume, and mixed with the PNA solution.
Growth medium was removed from cells and
replaced by the transfection solution for 4 h at
37°C. After PNA treatment, cells were supple-
mented with 10% FBS and incubated further for
20 h without removing the transfection solution.
PEI-PNA. Cys-PNA (PNA3140) was left to react
with PEI-PEGP15 in HEPES (20 mM, pH 7.4)
for one hour (PEG8-PDP:PNA ratio = 1:1) to
create PEI25K-(PEG8-SS-PNA)15. Then J volume
of PEI25K-(PEG8-SS-PNA)15 was mixed with L of
OPTI-MEM. Growth medium was removed from
cells and replaced by the transfection solution for
4 h at 37°C. After PNA treatment, cells were supple-
mented with 10% FBS and incubated further for
20 h without removing the transfection solution.
Luciferase assay. Twenty-four hours after treat-
ment, cells were subjected to luciferase activity analy-
sis by using the Bright-Glo Luciferase assay system (Promega).
Measurements were performed according to the manufacturer’s
instructions. Luminescence readings obtained with the Bright-
Glo Luciferase assay system are presented as relative light units
(RLU). Cells were lysed with 100 ml/well of Passive Lysis Buffer
(Promega) for 10 min and used for both luciferase and viability
assays. Luminescence readings were normalized by cell viability.
Luciferase activity normalization. For cells transfected on
96 well plates luciferase activity was normalized by cell viability
and shown as RLU/cell; Ten microliters of cell lysate were
diluted with 40 mlH 2O and analyzed for ATP content by using
CellTiter-Glo Luminescent Cell Viability Assay (Promega)
according to the manufacturer’s directions. The values were
presented as relative cellular viability (the value from non-PNA
treated cells was set as 100%).
Figure4. Relative cellular luciferase antisense activity of PNA conjugated to PEI
[PEI25K-(PEG8-SS-PNA)15]. HeLa pLuc705 cells were trypsinized and seeded in a 96 well
plate at different cell numbers the day before transfection. Cells were treated with
different volumes (50 ml/well for a relative volume 1) of the transfection solutions
for 24 h: (A) 1 mM or (B) 2 mM PNA (PDP:PNA; 1:1). Cell samples were then subjected to
luciferase analysis and cellular viability test. All tests were performed in triplicate and
the results are given as average values ± standard error of the mean (SEM). Luciferase
activity was analyzed using Bright-Glo reagent (Promega), normalized to cell viability
(Figs. S1–5) and given as relative light units (RLU/cell).
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For cells transfected on 24-well plates, luciferase activity was
normalized by protein concentrations, which were determined by
the BCA protein assay (Pierce) according to the manufacturer’s
instruction.
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